Pharmacological and metabolic characterisation of the potent σ1 receptor ligand 1′-benzyl-3-methoxy-3H-spiro[[2] benzofuran-1,4′-piperidine]

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 5, 2009, Pages 631-640

  Wiese, Christian ^a   Maestrup, Eva Große ^a   Schepmann, Dirk ^a   Vela, Jose Miguel ^b   Holenz, Jörg ^b   Buschmann, Helmut ^b   Wünsch, Bernhard ^a  

^a INST OF REPRO MED OF THE UNIV   (Germany)

^b ESTEVE   (Spain)

Author keywords

1 receptor antagonists; Analgesic activity; Metabolism; Recombinant CYP isoenzymes; Spirocyclic piperidines

Indexed keywords

1' BENZYL 3 METHOXY 3H SPIRO[[2]]BENZOFURAN 1,4' PIPERIDINE]; CAPSAICIN; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; ION CHANNEL; ISOENZYME; NEUROTRANSMITTER TRANSPORTER; POTASSIUM CHANNEL HERG; RADIOLIGAND; RECOMBINANT ENZYME; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG; 1' BENZYL 3 METHOXY 3H SPIRO((2)BENZOFURAN 1,4' PIPERIDINE); 1'-BENZYL-3-METHOXY-3H-SPIRO((2)BENZOFURAN-1,4'-PIPERIDINE); ANALGESIC AGENT; LIGAND; PIPERIDINE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ANALGESIC ACTIVITY; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IC 50; LIGAND BINDING; LIVER MICROSOME; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PAIN; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; RADIOASSAY;

ANALGESICS; ANIMALS; CAPSAICIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIGANDS; MICE; MICROSOMES, LIVER; PAIN; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, SIGMA;

EID: 65349124943     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.05.0012     Document Type: Article

References (38)

1. Martin WR et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-532.
2. Tam SW. Naloxone-inaccessible sigma receptor in rat central nervous system. Proc Natl Acad Sci USA 1983; 80: 6703-6707.
3. Gundlach AL et al. Phencyclidine and s opiate receptors in brain: biochemical and autoradiographical differentiation. Eur J Pharmacol 1985; 113: 465-466.
4. Kaiser C et al. Sigma receptor ligands: function and activity. Neurotransmission 1991; 7: 1-5.
5. Walker JM et al. Sigma receptors: biology and function. Pharmacol Rev 1990; 42: 353-402.
6. Danso-Danquah R et al. Synthesis and s binding properties of 2́-substituted 5,9α-dimethyl-6,7-benzomorphans. J Med Chem 1995; 38: 2978-2985.
7. Hanner M et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 1996; 93: 8072-8077.
8. Seth P et al. Cloning and functional characterization of a receptor from rat brain. J Neurochem 1998; 70: 922-932.
9. Kekuda R et al. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Comm 1996; 229: 553-558.
10. Aydar E et al. The sigma receptor as a ligand regulated auxiliary potassium channel subunit. Neuron 2002; 34: 399-410.
11. Hellewell SB et al. Rat liver and kidney contain high densities of σ-1 and σ-2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994; 268: 9-18.
12. Hong W et al. Modulation of bradykinin-induced calcium changes in SH-SY5Y cells by neurosteroids and sigma receptor ligands via a shared mechanism. Synapse 2004; 54: 102-110.
13. Bermack JE, Debonnel G. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse 2005; 55: 37-44.
14. Gudelsky GA. Biphasic effect of sigma receptor ligands on the extracellular concentration of dopamine in the striatum of the rat. J Neural Transm 1999; 106: 849-856.
15. Bowen WD. Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv 2000; 74: 211-218.
16. + channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors. J Physiol 1999; 517: 391-406.
17. Aydar E et al. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res 2004; 64: 5029-5035.
18. 2+: clinical and therapeutic relevance. Biol Cell 2005; 97: 873-883.
19. Zhang H, Cuevas J. Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons. J Neurophysiol 2002; 87: 2867-2879.
20. Rowley M et al. Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 2001; 44: 477-501.
21. Anon. Monograph igmesine hydrochloride. Drugs Fut 1999; 24: 133-140.
22. Skuza G. Potential anidepressant activity of sigma ligands. Pol J Pharmacol 2003; 55: 923-934.
23. Maurice T, Lockhart BP. Neuroprotective and anti-amnesic potentials of s (sigma) receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 69-102.
24. Marrazzo A et al. Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuroreport 2005; 18: 1223-1226.
25. Matsumotoa RR et al. σ-Receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol 2003; 496: 1-12.
26. 1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004; 18: 269-284.
27. Gilchrist HD et al. Enhanced withdrawal responses to heat and mechanical stimuli following intraplantar injection of capsaicin in rats. Pain 1996; 67: 179-188.
28. Baeyens JM. Use of compounds active at the sigma receptor for the treatment of allodynia. PCT Int Appl WO 2006/010587 A1 2006.
29. Kim KW et al. Selective sigma-1 receptor antagonist produces antinociceptive effect in neuropathic pain models in rats. FASEB J 2008; 22: lb618.
30. Entrena JM et al. Sigma-1 receptor agonists sensitize mice to capsaicin-induced mechanical allodynia. Behav Pharmacol 2005; 16(Suppl. 1): S107.
31. 1) knockout mice. Eur J Neurosci 2003; 18: 2188-2196.
32. Maier CA, Wünsch B. Novel spiropiperidines as highly potent and subtype selective σ-receptor ligands. Part 1. J Med Chem 2002; 45: 438-448.
33. Maier CA, Wünsch B. Novel s receptor ligands. Part 2. SAR of spiro[[2]benzopyran-1,4′-piperidines] and spiro[[2]benzofuran-1,4′- piperidines] with carbon substituents in position 3. J Med Chem 2002; 45: 4923-4930.
34. + channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005; 25: 133-166.
35. Plásek J, Sigler K. Slow fluorescent indicators of membrane potential: a survey of different approaches to probe response analysis. J Photochem Photobiol 1996; 33: 101-124.
36. Warnke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Nat Acad Sci USA 1994; 91: 3438-3442.
37. Dayer P, Gasser R. Characterization of a common genetic defect of cytochrome P-450 function. Biochem Biophys Res Commun 1984; 30: 374-380.
38. Testa B, Jenner P. Drug Metabolism: Chemical and Biochemical Aspects. Drugs and the Pharmaceutical Sciences Series, vol. 4, Swarbrick J, ed. New York: Marcel Dekker, 1976: 82.